EA200970360A1 - Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в - Google Patents
Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-вInfo
- Publication number
- EA200970360A1 EA200970360A1 EA200970360A EA200970360A EA200970360A1 EA 200970360 A1 EA200970360 A1 EA 200970360A1 EA 200970360 A EA200970360 A EA 200970360A EA 200970360 A EA200970360 A EA 200970360A EA 200970360 A1 EA200970360 A1 EA 200970360A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- reduce
- dyslipidemia
- omega
- levels
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Способ применения комбинированного введения или стандартной дозировки комбинации средства для лечения дислипидемии и омега-3 жирных кислот для снижения уровней аполипопротеина-В. Данные способы, в частности, можно применять при лечении пациентов с гиперхолестеринемией, гипертриглицеридемией, смешанной дислипидемией, коронарной болезнью сердца (CHD), сосудистыми заболеваниями, атеросклеротическими заболеваниями и связанными с ними состояниями, и для предупреждения или уменьшения сердечно-сосудистых, сердечных и сосудистых явлений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85028006P | 2006-10-10 | 2006-10-10 | |
PCT/US2007/021631 WO2008045465A1 (en) | 2006-10-10 | 2007-10-10 | Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200970360A1 true EA200970360A1 (ru) | 2009-10-30 |
Family
ID=39283166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970359A EA018734B1 (ru) | 2006-10-10 | 2007-09-07 | СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B |
EA200970360A EA200970360A1 (ru) | 2006-10-10 | 2007-10-10 | Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970359A EA018734B1 (ru) | 2006-10-10 | 2007-09-07 | СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2089014A4 (ru) |
JP (1) | JP2010505956A (ru) |
KR (1) | KR20090080070A (ru) |
CN (2) | CN101553221A (ru) |
AU (1) | AU2007307007A1 (ru) |
BR (1) | BRPI0719182A2 (ru) |
CA (1) | CA2672919A1 (ru) |
EA (2) | EA018734B1 (ru) |
MX (1) | MX2009003921A (ru) |
WO (1) | WO2008045465A1 (ru) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
JP2010506920A (ja) * | 2006-10-18 | 2010-03-04 | リライアント・ファーマシューティカルズ・インコーポレイテッド | Lp−pla2濃度を減少させるためのオメガ−3脂肪酸 |
US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
KR20140007973A (ko) | 2009-02-10 | 2014-01-20 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT |
CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
JP6227535B2 (ja) * | 2012-08-30 | 2017-11-08 | 株式会社三和化学研究所 | 脂質異常症の予防又は治療薬 |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
UA120922C2 (uk) * | 2014-02-05 | 2020-03-10 | Дезима Фарма Б.В. | Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014359A1 (en) * | 2001-03-16 | 2004-02-19 | Thomas Jefferson University | Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
MX2007006707A (es) * | 2004-12-06 | 2008-01-16 | Reliant Pharmaceuticals Inc | Acidos grasos omega-3 y agente dislipidemico para terapia lipidica. |
WO2007011886A2 (en) * | 2005-07-18 | 2007-01-25 | Reliant Pharmaceuticals, Inc. | Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof |
-
2007
- 2007-09-07 CN CNA2007800456489A patent/CN101553221A/zh active Pending
- 2007-09-07 EA EA200970359A patent/EA018734B1/ru not_active IP Right Cessation
- 2007-10-10 CN CNA2007800456667A patent/CN101553220A/zh active Pending
- 2007-10-10 WO PCT/US2007/021631 patent/WO2008045465A1/en active Application Filing
- 2007-10-10 MX MX2009003921A patent/MX2009003921A/es unknown
- 2007-10-10 EP EP07852630A patent/EP2089014A4/en not_active Withdrawn
- 2007-10-10 AU AU2007307007A patent/AU2007307007A1/en not_active Abandoned
- 2007-10-10 CA CA002672919A patent/CA2672919A1/en not_active Abandoned
- 2007-10-10 BR BRPI0719182-0A2A patent/BRPI0719182A2/pt not_active Application Discontinuation
- 2007-10-10 KR KR1020097009523A patent/KR20090080070A/ko not_active Application Discontinuation
- 2007-10-10 JP JP2009532391A patent/JP2010505956A/ja active Pending
- 2007-10-10 EA EA200970360A patent/EA200970360A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EA018734B1 (ru) | 2013-10-30 |
CA2672919A1 (en) | 2008-04-17 |
JP2010505956A (ja) | 2010-02-25 |
AU2007307007A1 (en) | 2008-04-17 |
KR20090080070A (ko) | 2009-07-23 |
CN101553221A (zh) | 2009-10-07 |
CN101553220A (zh) | 2009-10-07 |
BRPI0719182A2 (pt) | 2014-10-21 |
MX2009003921A (es) | 2009-08-31 |
EA200970359A1 (ru) | 2009-10-30 |
WO2008045465A1 (en) | 2008-04-17 |
EP2089014A4 (en) | 2009-12-09 |
EP2089014A1 (en) | 2009-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970360A1 (ru) | Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в | |
NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
CY1122629T1 (el) | Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
NZ595789A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
EA201001365A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ | |
JP2006501240A5 (ru) | ||
NO20064186L (no) | Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod | |
ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
CL2004000639A1 (es) | Compuestos derivados de quinolina y quinoxalina, composicion farmaceutica, combinacion farmaceutica; kit farmaceutico; y su uso para tratar aterosclerosis, enfermedad de arteria coronaria, enfermedad cardiaca coronaria, enfermedad vascular coronaria, | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
DE602006014691D1 (de) | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN | |
NO20076382L (no) | Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer | |
NO20076121L (no) | Behandlinger for kardiovaskulaer sykdom | |
NO20064755L (no) | Kombinasjonsterapi | |
ATE447973T1 (de) | Kombinationstherapie mit azd-2171 | |
CN101249108B (zh) | 一种蜂王浆酸性合剂和制备方法及其应用 | |
ATE409039T1 (de) | Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839 | |
Nasrat et al. | A therapeutic answer for the controversy of insulin cardio-protection among dysglycemic patients | |
DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations | |
Shimpi et al. | Role of Extra Corporeal Shock Wave Therapy (ESWT) in the Management of Peyronie's Disease: A Preliminary Report | |
RU2006142622A (ru) | Способ лечения острого инфаркта миокарда |